tiprankstipranks
Trending News
More News >
Hyperfine Inc. (HYPR)
:HYPR
US Market
Advertisement

Hyperfine (HYPR) AI Stock Analysis

Compare
130 Followers

Top Page

HYPR

Hyperfine

(NASDAQ:HYPR)

Rating:57Neutral
Price Target:
$1.50
▲(21.95% Upside)
Hyperfine's overall stock score is driven by strong technical momentum and positive earnings call insights, indicating potential growth and strategic advancements. However, significant profitability challenges and valuation concerns due to ongoing losses weigh down the score.
Positive Factors
Market Expansion
The company has established 13 new distributors in Europe, the Middle East, and Asia.
Product Innovation
HYPR is partnering with NVIDIA to develop future technologies that incorporate NVIDIA's advanced artificial intelligence (AI) capabilities with the Swoop system.
Negative Factors
Revenue Performance
Revenue of $2.1M missed both consensus and our estimate ($2.8M) by ~$0.7M.
Sales Challenges
HYPR is seeing an elongation in their selling cycle of up to ~18 months due to ongoing softness in the hospital capital environment.

Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)

Hyperfine Business Overview & Revenue Model

Company DescriptionHyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
How the Company Makes MoneyHyperfine generates revenue primarily through the sale and leasing of its Swoop portable MRI systems. The company also earns income from service contracts, offering maintenance and technical support for their equipment. Additional revenue streams may include training services for medical staff and software updates for the MRI systems. Significant partnerships with healthcare providers and research institutions further enhance its market reach and adoption of its innovative MRI technology.

Hyperfine Earnings Call Summary

Earnings Call Date:Aug 13, 2025
(Q2-2025)
|
% Change Since: -3.15%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call revealed strong revenue growth and strategic advancements, notably in FDA clearances and the launch of the next-generation Swoop system. Despite a net loss and some deal delays, the positive trajectory in revenue, margin expansion, and international presence suggests a favorable outlook.
Q2-2025 Updates
Positive Updates
Revenue Growth
Revenue for the second quarter of 2025 was $2.7 million, up 26% sequentially.
FDA Clearances
Hyperfine received FDA clearance for two major new technologies, ahead of their planned schedule.
Gross Margin Expansion
Gross margins expanded by approximately 800 basis points sequentially, reaching 49%.
Next-Generation Swoop System Launch
Successful launch of the next-generation Swoop system, featuring transformative image quality, with the first sale completed within 30 days of FDA clearance.
Cash Burn Reduction
Cash burn was reduced by 19% sequentially, excluding financings.
International Expansion
Optive AI software is now available in Canada, Australia, and New Zealand, with plans to launch in Europe by the end of 2025.
Negative Updates
Net Loss
Net loss for the second quarter of 2025 was $9.2 million, equating to a net loss of $0.12 per share.
Delayed Deals
A second next-generation system deal was delayed and closed after the quarter end, affecting potential revenue for the quarter.
Reliance on NIH Grants
Early in 2025, a few deals were delayed due to NIH grant cancellations, although future pipeline does not rely on such funding.
Company Guidance
During the second quarter of 2025, Hyperfine achieved significant milestones, reporting $2.7 million in revenue with an increase of 26% sequentially, driven by the sale of eight systems, including the first next-generation Swoop system. Gross margins expanded by approximately 800 basis points to 49%, and cash burn was reduced by 19% sequentially, excluding financings. The company received FDA clearance for two new technologies and launched the next-generation Swoop system powered by Optive AI software, which has been well-received in the market. Hyperfine is targeting a total market opportunity exceeding $6 billion with its AI-enabled portable MR technology, which offers high-quality brain imaging across various care settings. The next-generation Swoop system has an MSRP of $550,000, a 15% premium over the previous version, and Hyperfine aims for significant revenue growth in the second half of 2025, with expectations for gross margins between 47% and 50% for the full year. The company is focusing on U.S. hospitals, office settings, and international markets to drive growth and leverage going forward, with a cash runway extending to the end of 2026.

Hyperfine Financial Statement Overview

Summary
Hyperfine shows strong revenue growth and a solid equity position with no debt. However, persistent net losses and negative cash flows highlight significant profitability challenges. The high equity ratio and lack of debt provide stability, but the negative ROE and cash flow issues indicate a need for improved operational efficiency.
Income Statement
30
Negative
Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.
Balance Sheet
55
Neutral
The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.
Cash Flow
40
Negative
Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.80M12.89M11.03M6.81M1.50M294.00K
Gross Profit4.95M5.89M4.76M907.00K-1.17M-477.00K
EBITDA-41.50M-42.22M-47.06M-72.86M-64.14M-23.20M
Net Income-39.36M-40.72M-44.24M-73.16M-64.83M-23.36M
Balance Sheet
Total Assets45.23M58.90M94.20M134.05M202.47M71.53M
Cash, Cash Equivalents and Short-Term Investments25.42M37.65M75.18M117.47M188.50M62.68M
Total Debt250.00K269.00K185.00K0.000.00178.00K
Total Liabilities10.11M9.86M9.80M10.33M16.25M132.58M
Stockholders Equity35.13M49.04M84.40M123.72M186.23M-61.05M
Cash Flow
Free Cash Flow-35.19M-39.15M-42.61M-72.92M-49.89M-23.09M
Operating Cash Flow-34.03M-38.77M-41.81M-72.34M-47.18M-21.52M
Investing Cash Flow-1.16M-383.00K-804.00K-585.00K-2.71M-1.57M
Financing Cash Flow6.96M1.02M174.00K7.00K176.77M60.94M

Hyperfine Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.23
Price Trends
50DMA
0.96
Positive
100DMA
0.83
Positive
200DMA
0.91
Positive
Market Momentum
MACD
0.10
Positive
RSI
55.57
Neutral
STOCH
28.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 1.23 is above the 20-day moving average (MA) of 1.19, above the 50-day MA of 0.96, and above the 200-day MA of 0.91, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 55.57 is Neutral, neither overbought nor oversold. The STOCH value of 28.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Risk Analysis

Hyperfine disclosed 77 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Hyperfine Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$95.34M12.385.00%0.29%-22.13%
65
Neutral
¥352.94B11.56-1.45%2.37%9.60%-12.34%
57
Neutral
$98.86M-77.26%-9.59%8.78%
51
Neutral
$25.15M-262.03%2.65%70.21%
43
Neutral
$59.08M-230.80%-16.46%4.16%
39
Underperform
$38.15M-125.63%6.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYPR
Hyperfine
1.23
0.19
18.27%
FONR
Fonar
15.22
-2.03
-11.77%
RBOT
Vicarious Surgical
6.38
-0.50
-7.27%
VVOS
Vivos Therapeutics
4.60
1.90
70.37%
ICCM
Icecure Medical
0.88
0.18
25.71%

Hyperfine Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Hyperfine Regains Nasdaq Compliance with Bid Price
Positive
Aug 6, 2025

On April 30, 2025, Hyperfine, Inc. was notified by Nasdaq that its Class A common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days. However, by August 6, 2025, Hyperfine regained compliance with the Nasdaq’s bid price requirement, thus resolving the issue.

Executive/Board Changes
Hyperfine Chairperson R. Scott Huennekens Resigns
Neutral
May 23, 2025

On May 21, 2025, R. Scott Huennekens, Chairperson of Hyperfine, Inc.’s Board of Directors, announced his resignation effective May 22, 2025, due to personal reasons and other commitments. His departure was not due to any disagreements with the company. The Board expressed gratitude for his service since 2021 and, in response, reduced its size from six to five members. Daniel J. Wolterman, a current board member, was appointed as the new Chairperson, and the company anticipates his leadership.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025